ATE365537T1 - Wässrige dispersion stabiler nanopartikel eines wasserunlöslichen wirkstoffs und ein hilfsstoff wie mittelkettige triglyceride (mct) - Google Patents

Wässrige dispersion stabiler nanopartikel eines wasserunlöslichen wirkstoffs und ein hilfsstoff wie mittelkettige triglyceride (mct)

Info

Publication number
ATE365537T1
ATE365537T1 AT02745697T AT02745697T ATE365537T1 AT E365537 T1 ATE365537 T1 AT E365537T1 AT 02745697 T AT02745697 T AT 02745697T AT 02745697 T AT02745697 T AT 02745697T AT E365537 T1 ATE365537 T1 AT E365537T1
Authority
AT
Austria
Prior art keywords
water
medium
mct
excipient
active substance
Prior art date
Application number
AT02745697T
Other languages
German (de)
English (en)
Inventor
Pia Skantze
Tommy Skantze
Corswant Lars Von
Schantz Anna Zzackrisson
Per Lindfors
Ulf Olsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0119081A external-priority patent/GB0119081D0/en
Priority claimed from GB0212463A external-priority patent/GB0212463D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE365537T1 publication Critical patent/ATE365537T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
AT02745697T 2001-08-06 2002-08-01 Wässrige dispersion stabiler nanopartikel eines wasserunlöslichen wirkstoffs und ein hilfsstoff wie mittelkettige triglyceride (mct) ATE365537T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0119081A GB0119081D0 (en) 2001-08-06 2001-08-06 Process
GB0212463A GB0212463D0 (en) 2002-05-30 2002-05-30 Process

Publications (1)

Publication Number Publication Date
ATE365537T1 true ATE365537T1 (de) 2007-07-15

Family

ID=26246405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745697T ATE365537T1 (de) 2001-08-06 2002-08-01 Wässrige dispersion stabiler nanopartikel eines wasserunlöslichen wirkstoffs und ein hilfsstoff wie mittelkettige triglyceride (mct)

Country Status (19)

Country Link
US (1) US20050009908A1 (https=)
EP (1) EP1416917B1 (https=)
JP (1) JP4714412B2 (https=)
KR (1) KR100914113B1 (https=)
CN (1) CN1254233C (https=)
AT (1) ATE365537T1 (https=)
AU (1) AU2002317409B2 (https=)
BR (1) BR0211705A (https=)
CA (1) CA2456180C (https=)
CY (1) CY1107059T1 (https=)
DE (1) DE60220923T2 (https=)
DK (1) DK1416917T3 (https=)
ES (1) ES2287293T3 (https=)
IL (2) IL160103A0 (https=)
MX (1) MXPA04001071A (https=)
NO (1) NO20040484L (https=)
NZ (1) NZ530916A (https=)
PT (1) PT1416917E (https=)
WO (1) WO2003013472A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
EP1641779A1 (en) * 2003-06-18 2006-04-05 AstraZeneca AB 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
US20080193534A1 (en) * 2005-08-12 2008-08-14 Astrazeneca Ab Process
EP2054036B1 (en) 2006-07-24 2019-12-18 Singh-Broemer and Company, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
US20100260691A1 (en) * 2006-07-31 2010-10-14 Narayanan Kolazi S Aqueous compositions containing a hydrophobic material
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
WO2008097165A1 (en) * 2007-02-09 2008-08-14 Astrazeneca Ab Process for preparation of a stable dispersion of solid amorphous submicron particles in an aqueous medium
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
EP2178893A4 (en) * 2007-07-16 2012-09-19 Poniard Pharmaceuticals Inc ORAL FORMULATIONS FOR PICOPLATIN
WO2009099649A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
BRPI1004808B1 (pt) * 2010-10-27 2020-09-29 Embrapa - Empresa Brasileira De Pesquisa Agropecuária Composições baseadas em nanopartículas de própolis, processos de obtenção e uso
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
KR102045732B1 (ko) * 2012-12-28 2019-11-18 엘지디스플레이 주식회사 온도감응형 계면활성제를 이용한 수용성 나노입자의 제조방법
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
EP2954009A1 (de) * 2013-02-08 2015-12-16 Basf Se Herstellung von anorganisch-organischen kompositmaterialien durch reaktive sprühtrocknung
WO2019055525A1 (en) * 2017-09-12 2019-03-21 Raj Selvaraj FORMULATION OF SOLID NANOPARTICLES OF WATER-INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD CURING
IL312564A (en) 2021-11-05 2024-07-01 Cinclus Pharma Holding Ab Publ Polymorphs of the hydrochloride salt of linfarezan glurate

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2224133B2 (de) * 1972-05-17 1974-06-20 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von bestimmten Mikroorganismen-Stämmen zur Gewinnung von Cholesterinoxydase, welche Cholesterin mit O tief 2 zu Cholestenon + H tief 2 O tief 2 oxydiert
US4348385A (en) * 1980-11-17 1982-09-07 Mobay Chemical Corporation Flowable pesticides
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US4799962A (en) * 1987-12-24 1989-01-24 Aqualon Company Water-soluble polymer dispersion
US5145648A (en) * 1988-06-28 1992-09-08 Matsushita Electric Industrial Co., Ltd. Exhaust smoke purifier apparatus
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
DE69112917T2 (de) * 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2125282C (en) * 1991-12-05 1999-08-31 Jens-Christian Wunderlich Pharmaceutically applicable nanosol and process for preparing the same
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468604A (en) * 1992-11-18 1995-11-21 Eastman Kodak Company Photographic dispersion
GB9319129D0 (en) * 1993-09-15 1993-11-03 Dowelanco Ltd Storage and dilution of stable aqueous dispersions
SE9303281D0 (sv) * 1993-10-07 1993-10-07 Astra Ab New formulation
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
DE69727244T2 (de) * 1996-10-03 2004-11-25 Hermes Biosciences Inc., San Francisco Hydrophile Mikroteilchen und Verfahren zu deren Herstellung
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations

Also Published As

Publication number Publication date
JP4714412B2 (ja) 2011-06-29
MXPA04001071A (es) 2004-05-20
CN1254233C (zh) 2006-05-03
DE60220923D1 (de) 2007-08-09
DE60220923T2 (de) 2008-03-06
EP1416917A1 (en) 2004-05-12
KR20040025739A (ko) 2004-03-25
NZ530916A (en) 2005-07-29
KR100914113B1 (ko) 2009-08-27
IL160103A0 (en) 2004-06-20
DK1416917T3 (da) 2007-09-17
ES2287293T3 (es) 2007-12-16
IL160103A (en) 2008-11-26
EP1416917B1 (en) 2007-06-27
US20050009908A1 (en) 2005-01-13
BR0211705A (pt) 2004-09-28
CY1107059T1 (el) 2012-10-24
CN1564677A (zh) 2005-01-12
CA2456180C (en) 2011-10-11
WO2003013472A1 (en) 2003-02-20
HK1064048A1 (en) 2005-01-21
AU2002317409B2 (en) 2007-06-21
CA2456180A1 (en) 2003-02-20
NO20040484L (no) 2004-03-31
PT1416917E (pt) 2007-08-16
JP2005500362A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
ATE365537T1 (de) Wässrige dispersion stabiler nanopartikel eines wasserunlöslichen wirkstoffs und ein hilfsstoff wie mittelkettige triglyceride (mct)
Al-Khattaf Gold and silver nanoparticles: Green synthesis, microbes, mechanism, factors, plant disease management and environmental risks
Rai et al. Biogenic nanoparticles: an introduction to what they are, how they are synthesized and their applications
Zhao et al. Translocation, distribution and degradation of prochloraz-loaded mesoporous silica nanoparticles in cucumber plants
Nene et al. Synthetic preparations and atomic scale engineering of silver nanoparticles for biomedical applications
Arya et al. Chitosan nanoparticles and their combination with methyl jasmonate for the elicitation of phenolics and flavonoids in plant cell suspension cultures
Handoko et al. Synthesis pathway and powerful antimicrobial properties of silver nanoparticle: a critical review
WO2005038948A3 (en) Nanosized silver oxide powder
EP1829530A3 (en) Stabilization of active agents by formulation into nanoparticulate form
WO2002096457A3 (en) Stable liquid formulations of antibodies
ATE332756T1 (de) Selbstreinigende sprühdüse
WO2004071466A3 (en) Manufacturing process for liposomal preparations
GB0302673D0 (en) Pharmaceutical formulations
DE502006005846D1 (de) Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
Verma et al. Exploration of biodegradable polymeric particles in agriculture: a holistic approach for sustainable farming
Dong et al. Instantaneous and continuous preparation of avermectin nanoparticles with high gravity anti-solvent precipitation technology
Pattapulavar et al. Nanogels applications in nutrient delivery and plant growth promotion
Chaturvedi et al. Antimicrobial nanoparticles: a new horizon to combat multidrug-resistant bacteria
CN104561105B (zh) 一种血红密孔菌生物合成金纳米颗粒的方法及其应用
Chhabra et al. Nano‐Pesticides, Nano‐Herbicides and Nano‐Fertilizers: Future Perspective
Yoo et al. Bacterial indoleacetic acid-induced synthesis of colloidal Ag2O nanocrystals and their biological activities
KR101625011B1 (ko) 제타전위값 상승을 유도한 친환경 액상 비료 조성물의 제조 방법
ATE440594T1 (de) Herstellung von kolloidale teilchen enthaltenden pulvern
Mie et al. A review on biosynthesis of nanoparticles using plant extract: An emerging green nanotechnology
Gulzar et al. Nanotechnology-enhanced phytonutraceuticals: Innovations in characterization, formulation, and therapeutic applications

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1416917

Country of ref document: EP